Phenylpiracetam

Piracetam with a phenyl group attached — a Russian modification that adds a distinctly stimulant edge. Notable for being banned by WADA, which is the strongest third-party endorsement any nootropic in this class has received.

Phenylpiracetam is piracetam with a phenyl ring attached, a modification that makes it fat-soluble enough to cross into the brain more readily and gives it stimulant properties the parent compound lacks. Proposed mechanisms include effects on dopamine, noradrenaline and acetylcholine signalling alongside the poorly-defined racetam actions. Which of those matters at the amounts people take has not been resolved — and the honest summary is that its stimulant character is what users notice, whatever the underlying pathway.

Russian trials in stroke/asthenia report cognitive and physical benefit. In healthy users, the acute stimulant effect is real and noticeable (hence the WADA ban); rapid tolerance is near-universally reported, which caps it as an occasional tool rather than a daily driver. Western RCTs in healthy adults: none.

• It is approved in Russia and some neighbouring countries under the name Phenotropil, which is where its clinical literature comes from. It is not approved anywhere in the West.
• The published trials are Russian-language, small, and conducted in patient groups — stroke recovery, vertebrobasilar insufficiency, post-traumatic epilepsy as an adjunct — rather than in healthy people. Several are open-label.
• NONE SHOWN for cognitive enhancement in healthy adults, which is the use it is bought for in the West.
• It is prohibited in sport as a stimulant and has produced anti-doping violations, which is how most Western awareness of it arose.
• Tolerance to its stimulant effect is widely described by users and is consistent with its pharmacology, though it has not been formally characterised.

Orally active and more lipid-soluble than piracetam. Human pharmacokinetics outside the Russian literature are poorly characterised. What reaches Western buyers is research-chemical supply of unverified identity and purity rather than the approved pharmaceutical.

Stimulant-profile effects: sleep disruption, irritability, blood-pressure bump. Tolerance within days. Same unregulated-supply caveat as every Russian compound here. Athletes: it is prohibited and produces doping violations.

• Anyone in tested sport, where it is prohibited
• Anyone with cardiovascular disease or uncontrolled hypertension
• Anyone with an anxiety or sleep disorder
• Anyone pregnant or breastfeeding
• Anyone unwilling to accept unverified research-chemical supply

• Other stimulants including caffeine, where cardiovascular and sleep effects are additive.
• Tested sport, where it is prohibited.
• No adequately characterised human interaction profile exists outside the Russian literature.

• Sleep, which stimulants degrade and which then undoes what the compound was taken for.
• Blood pressure and heart rate.
• Anxiety and irritability, commonly reported with the stimulating racetams.
• Whether use has become daily, since tolerance to the stimulant effect is widely described.

No withdrawal syndrome is described in the available literature. What people report on stopping is the fatigue that follows any stimulant, plus the return of whatever sleep debt accumulated. Since no controlled evidence establishes benefit in healthy people, there is no established effect to lose.

US: unscheduled, grey-market sale. Prescription in Russia. WADA-banned in sport.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• The use of phenotropil in vertebrobasilar insufficiency
  Zh Nevrol Psikhiatr Im S S Korsakova, 2013
• Efficacy of phenotropil in the rehabilitation of stroke patients
  Zh Nevrol Psikhiatr Im S S Korsakova, 2010
• Phenotropil use as premedication during out-patient stomatological treatment
  Stomatologiia (Mosk), 2008

• S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activityPharmacol Biochem Behav · 2017
• Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male miceInflammopharmacology · 2020
• Asymmetric Michael Addition in Synthesis of β-Substituted GABA DerivativesMolecules · 2022
• Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disordersDrugs · 2010
• [Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use]Zh Nevrol Psikhiatr Im S S Korsakova · 2024
• [Pharmacological characteristics of a new phenyl analog of piracetam--4-phenylpiracetam]Biull Eksp Biol Med · 1983
• Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agentsDrug Test Anal · 2023
• Five Unapproved Drugs Found in Cognitive Enhancement SupplementsNeurol Clin Pract · 2021
• [Molecularly imprinted sorbent for biological fluids sample preparation in forensic toxicology]Sud Med Ekspert · 2021
• A study of the mechanisms for antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemiaBull Exp Biol Med · 2014
• [Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia]Eksp Klin Farmakol · 2015
• From Umpolung to Alternation: Modified Reactivity of Donor-Acceptor Cyclopropanes Towards Nucleophiles in Reaction with NitroalkanesChemistry · 2016